Compare ORMP & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORMP | JSPR |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 49.5M |
| IPO Year | N/A | N/A |
| Metric | ORMP | JSPR |
|---|---|---|
| Price | $3.10 | $1.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $25.60 |
| AVG Volume (30 Days) | 251.8K | ★ 3.8M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 838.25 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.82 | $1.39 |
| 52 Week High | $3.20 | $23.11 |
| Indicator | ORMP | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 70.75 | 43.99 |
| Support Level | $2.66 | $1.61 |
| Resistance Level | $3.20 | $1.93 |
| Average True Range (ATR) | 0.14 | 0.21 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 70.38 | 29.61 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.